[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Quanli Gao\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100569376","the-immune-assessment-of-pd-1-antibody-therapy-in-tumor-100569376",false,"NCT06693440","The Immune Assessment of PD-1 Antibody Therapy in Tumor","The Immune Assessment of PD-1 Antibody Therapy in Tumor - A Case-Control Study","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Pathologically confirmed malignant tumors.\n3. Complete medical records.\n4. Assessable immune function test data.\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years.\n2. No confirmed tumor pathology.\n3. Untraceable medical records.\n4. Non-assessable immune function tests.","ALL","18 Years",{"count":19,"type":20},3000,"ESTIMATED","OBSERVATIONAL","This retrospective study will leverage previous immune function monitoring results in conjunction with clinical case data at this medical center.",[24,25],"Efficacy, Team","Adverse Event",[27,28,29],"PD(L)-1 inhibitor","efficacy","adverse event","RECRUITING","2024-11-14",{"date":33,"type":34},"2024-11-18","ACTUAL",{"date":36,"type":34},"2021-07-01",{"date":38,"type":20},"2030-11-13",{"name":40,"class":41},"Quanli Gao","OTHER_GOV",""]